Clinical trial · Observational
Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma
A Retrospective Clinical Study of Postoperative Concurrent Chemoradiotherapy Combined With Anti-angiogenic Drugs in the Treatment of Glioblastoma.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Temozolomide (TMZ) is an oral chemotherapy drug. It is an alkylating agent used as a first-line treatment for glioblastoma. This methylation damages the DNA and triggers the death of tumor cells. According to the results of several clinical studies, TMZ synchronous plus radiotherapy and subsequent as adjuvant therapy can significantly improve the survival rate of newly diagnosed glioblastoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Apatinib | Drug | — | UNRESOLVED |
| Temozolomide（TMZ） | Drug | Temozolomide | ALIAS |
Design
Arms and outcomes
Arms (3)
- label
- Experimental 1
- description
- concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide）
- interventionNames
- Drug: Apatinib
- Drug: Temozolomide（TMZ）
- label
- control
- description
- concurrent chemoradiotherapy（Temozolomide） maintenance therapy（Temozolomide）
- interventionNames
- Drug: Temozolomide（TMZ）
- label
- Experimental 2
- description
- concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide+apatinib）
- interventionNames
- Drug: Apatinib
- Drug: Temozolomide（TMZ）
Primary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Search Criteria: 1. Subjects received anti-angiogenesis drugs simultaneous accompanied with radio-and chemotherapy in Fuzhou Zongyuan since October, 2017; 2. Age: 18-70 years; 3. The first surgical pathology was diagnosed as glioblastoma, WHO grade III or IV; 4. Patients who have previously received no more than one surgical treatment; 5. ECOG performance status: 0-2; 6. Survival expectation≥3 months.
References
Publications (0)
Data not yet available